What is the human papillomavirus (HPV) testing market growth?

The global human papillomavirus (HPV) testing market is expected to grow at a compound annual growth rate of 12.0% from 2022 to 2032 to reach USD 13.0 Bn by 2032.

Which key players operating in the human papillomavirus (HPV) testing market?

Some of the prominent players operating in this market place are GlaxoSmithKline plc, Sanofi, Pifzer Inc, Merck & Co.Inc, Novartis AG, Emergent Biosolutions, CSL Limited, Xenetic Bioscienes Inc, Inovio Pharmaceuticals, Inc, Thymox Technology, Benefit Corporation, Bosque Solutions, Serum Institute of India Pvt.Ltd, Bharat Biotec.

How big is the human papillomavirus (HPV) testing market?

The global human papillomavirus (HPV) testing market size was estimated at USD 4.3 billion in 2022 and is expected to reach USD 4.8 billion in 2023.

Global Human Papillomavirus (HPV) Testing Market By Type (Bivalent, Polyvalent, and Quadrivalent ), By Disease Indication (HPV Associated Cancer and Genital Warts), By Distribution Channels (Hospitals Pharmacies, Retail Pharmacies, Government Suppliers, and Others), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Published date: Oct 2023
Report ID: 59786
Number of Pages: 319
Format:

- GlaxoSmithKline plc.
- Sanofi
- Pifzer Inc.
- Merck & Co. Inc.
- Novartis AG
- Emergent Biosolutions
- CSL Limited
- Xenetic Bioscienes Inc.
- Inovio Pharmaceuticals, Inc.
- Thymox Technology
- Benefit Corporation
- Bosque Solutions
- Serum Institute of India Pvt. Ltd
- Bharat Biotec.
- Other Key Players